Abstract
Reopening schools is an urgent priority as the COVID-19 pandemic drags on throughout much of the world. To explore the risks associated with returning to in-person learning and the value of mitigation measures in a school setting, we use the stochastic, network-based SEIRS+ epidemiological modeling platform to simulate SARS-CoV-2 transmission in schools. Because children and adolescents differ both in disease susceptibility and in patterns of social interaction, we use distinct models of SARS-CoV-2 transmission for primary and secondary school settings. We find that a number of mitigation measures may prove useful, particularly when community prevalence is low. Student cohorting, in which students are divided into two separate populations that attend in-person classes on alternating schedules, can reduce both the likelihood and the size of outbreaks. Proactive testing of teachers and staff once or twice a week can help catch introductions early, before they spread widely through the school. Especially in secondary schools, once- or twice-weekly testing amongst students should also be considered to further reduce the likelihood of a large outbreak amongst the full population. Vaccinating teachers and staff protects these individuals and may also have a disproportionate protective effect on the outbreak potential in primary and secondary schools when vaccines block SARS-CoV-2 transmission in addition to symptoms. Other mitigation strategies – including mask-wearing, social distancing, and increased ventilation – remain a crucial component of any reopening plan.
Competing Interest Statement
CTB and RSM consult for Color Health. CTB has received honoraria from Novartis. JRH, HEW and AYZ are currently employed by and have equity interest in Color Health.
Funding Statement
CTB and RSM were paid consulting fees by Color Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
Extensive documentation and code for the SEIRS+ framework that was developed and used to implement the Extended SEIR Network Model studied in this work can be found at github.com/ryansmcgee/seirsplus. The datasets generated by this work can be explored using an interactive web applet hosted at color.com/impact-of-primary-school-covid-19-testing. Simulation and statistics data will be accessible via the aforementioned github and otherwise made available upon request.
https://github.com/ryansmcgee/seirsplus
https://www.color.com/impact-of-primary-school-covid-19-testing
